Skip to main content
MindWalk Holdings Corp. logo

MindWalk Holdings Corp. — Investor Relations & Filings

Ticker · HYFT ISIN · CA45257F2008 US Professional, scientific and technical activities
Open in API
Filings indexed 256 across all filing types
Latest filing 2022-03-29 Regulatory Filings
Country US United States of America
Listing US HYFT

About MindWalk Holdings Corp.

https://www.ipatherapeutics.com/

MindWalk Holdings Corp. is a Bio-Native AI company that focuses on transforming drug discovery and development. The company operates a biointelligence ecosystem that integrates artificial intelligence, multi-omics data, and advanced laboratory research to make complex biology computable and actionable. This unified platform is designed to accelerate the discovery and development of biologics, including therapeutic antibodies, diagnostics, vaccines, and peptide therapeutics, from target identification through to the clinical stage. Its capabilities are powered by proprietary technologies such as the patented HYFT® technology and the LensAI™ platform, which are adaptable to specific targets, modalities, and program priorities.

Recent filings

Filing Released Lang Actions
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted pursuant to SEC rules. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1390 characters), and it primarily serves as a regulatory filing to report current information rather than a full financial report or earnings release. Therefore, it fits best under the Regulatory Filings (RNS) category, which is the fallback for miscellaneous filings that do not fit other specific categories.
2022-03-29 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC. It references a press release dated March 16, 2022, but does not contain detailed financial statements or substantive financial data. The document length is only 1390 characters, indicating it is a brief filing rather than a full report. Form 6-K filings typically serve as regulatory filings to disclose material information between annual reports. Therefore, this document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement without detailed financial content.
2022-03-16 English
FY22 Q3 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign issuer, ImmunoPrecise Antibodies Ltd., pursuant to SEC rules. It includes references to exhibits such as Management's Discussion and Analysis (MD&A), Condensed Interim Consolidated Financial Statements for the three and nine months ended January 31, 2022 and 2021, and CEO and CFO certifications. The document length is only 2052 characters, which is quite short and primarily serves as a cover report referencing attached exhibits rather than containing the full financial data itself. According to the MENU VS MEAL RULE, such a short document that states reports are attached or incorporated by reference should be classified as a Regulatory Filing (RNS) rather than the actual Interim Report (IR) or Management Discussion and Analysis (MDA). The presence of certifications also supports the RNS classification rather than the report itself. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2022-03-16 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, ImmunoPrecise Antibodies Ltd., pursuant to SEC rules. It includes a press release as an exhibit and is dated March 2022. The document length is short (1391 characters) and primarily serves as a regulatory filing to report current information to the SEC. It does not contain detailed financial statements or comprehensive reports such as annual or interim reports. It also does not fit into categories like earnings release or management reports. Given the nature and length, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-03-14 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 100% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1391 characters), and it primarily serves as a regulatory filing to report information to the SEC. According to the rules, such filings that do not contain full reports or detailed financial data are classified as Regulatory Filings (RNS).
2022-03-14 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC. It includes a press release dated March 8, 2022, but the document itself is short (1390 characters) and does not contain detailed financial statements or substantive financial data. It is primarily an announcement filing with an exhibit index referencing a press release. According to the rules, such filings that are brief and serve as announcements or submissions of external documents should be classified as Regulatory Filings (RNS).
2022-03-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.